BHCM
CRBP icon

Brevan Howard Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Brevan Howard Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$307K Buy
32,679
+13,884
+74% +$117K ﹤0.01% 1603
2025
Q4 		$153K Buy
+18,795
New +$232K ﹤0.01% 1631

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Brevan Howard Capital Management's CRBP Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Corbus Pharmaceuticals (CRBP) stake by 74% in Q1 2026, buying an estimated $117K and bringing the position to 32,679 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #1603.

Brevan Howard Capital Management first reported a position in CRBP in Q4 2025 and has held it in 2 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Brevan Howard Capital Management held 32,679 shares of Corbus Pharmaceuticals worth $307K as of Q1 2026.
  • Brevan Howard Capital Management bought 13,884 Corbus Pharmaceuticals shares in Q1 2026, an estimated $117K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1603 holding.
  • Brevan Howard Capital Management first reported a position in Corbus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.